Horizon's Genmab drug gets blockbuster status

After the first nine months of 2021, sales of Tepezza have crossed the important USD 1bn annual sales threshold.
Rare eye disease Graves' opthalmopathy has been a big money maker for Horizon Therapeutics. | Photo: Marijan Murat/AP/Ritzau Scanpix
Rare eye disease Graves' opthalmopathy has been a big money maker for Horizon Therapeutics. | Photo: Marijan Murat/AP/Ritzau Scanpix
by elizabeth mønsted johansen, translated by catherine brett

Horizon therapeutics has sold more than twice as much of its drug Tepezza during the first nine months of 2021 than it did during the same period last year, its Q3 report reveals.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading